We are excited to see the approval of tarlatamab, Amgen’s DLL3-targeted T cell engager, which provides small cell lung cancer patients with a much-needed new treatment option. This first approval of a T cell engager for a solid tumor indication highlights the ability of T cell engagers to greatly expand the populations of cancer patients who can benefit from the potentially curative power of immune therapy. At Phenomic AI, we are developing T cell engagers against novel solid tumor targets that we hope will benefit patients in the near future. #CancerResearch #Immunotherapy #TCellEngagers https://lnkd.in/eKjFXZwH
About us
Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets.
- Website
-
https://phenomic.ai
External link for Phenomic
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
661 University Ave
Toronto, Ontario, CA
Employees at Phenomic
Updates
-
We are excited to be working with TileDB to tackle big data challenges. Learn how we leveraged TileDB's robust platform for our groundbreaking work in single-cell RNA analysis. Read more here: https://lnkd.in/eKi_4dHH
🌟 We are excited to share our case study with Phenomic, a pioneering biotech company developing new medicines targeting tumor stroma. Their challenge? Identifying a future-proof database solution for storing and analyzing one of the world’s largest single-cell RNA (scRNA) datasets. In their own words: "TileDB was the best database and platform out there for our cloud workflows and unique domain of single-cell research." Read more 👇 https://hubs.la/Q02wN5bm0
Case Study: Phenomic AI | TileDB
-
Join us at AACR for a groundbreaking poster presentation titled "AI/ML-driven discovery of CTHRC1, collagen triple helix repeat-containing 1, a novel proteoglycan for stroma tumor targeting and delivery of T cell activators". Our CSO, Mike Briskin, will delve into the fascinating world of AI/ML-driven discovery and its implications for cancer therapeutics. 📅 Date: April 8th 🕜 Time: 1:30-5pm PT 📍 Session: PO.TB11.02 - The Tumor Microenvironment as a Drug Target Mike is thrilled to share insights and discuss our innovative approach to stroma tumor targeting and delivery of T cell activators. Don't miss this opportunity to connect, learn, and be inspired. See you there! #AACR #CancerResearch #AI #ML #Innovation
-
Happy International Women's Day! Today, we proudly honor and celebrate the remarkable female scientists driving innovation at Phenomic. 👩🔬 We're on a mission to transform cancer treatment and improve patient outcomes by tackling the intricate challenges posed by the tumor stroma. This dynamic group of women scientists is at the forefront of our groundbreaking efforts, working tirelessly to develop new medicines that break down barriers hindering today's cancer therapies. ⚗ Their dedication, brilliance, and passion are shaping the future of biotech, bringing hope to countless lives affected by cancer. Today, we recognize and celebrate these inspiring women who contribute their expertise, creativity, and resilience to make a meaningful difference in the world of science and healthcare. 🔬 Here's to the trailblazers, innovators, and leaders who inspire us every day! 🚀 #InternationalWomensDay #WomenInScience #PhenomicAI #Innovation #DiversityInSTEM #CancerResearch #EmpowerChange
-
Our CEO, Girish Aakalu, and CTO, Sam Cooper, will be participating in a #firesidechat at H.C. Wainwright's 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference. Connect with them to learn more about our recent progress and pipeline. #hcwainwright #artificialintelligence #drugdiscovery #phenomicai
-
-
#NEWS: Our new partnership with Astellas Pharma US will explore the ability of antibodies discovered by our unique platform, called scTx®, to enhance cell therapy approaches for #solidtumors. This collaboration demonstrates our dedication to overcoming the tumor stroma, a complex barrier that drives poor outcomes in a majority of solid tumors. Read more about our strategic collaboration here: https://lnkd.in/dHViXT9q #cancer #biotechnology #innovation #researchcollaboration
-
-
#NEWS: We are excited to partner with Boehringer Ingelheim to leverage our expertise in target identification and stromal biology to develop first-in-class medicines for patients with difficult-to-treat cancers. By applying our unique discovery platform, called scTx®, we will identify and validate novel targets to potentially overcome the barrier created by the tumor stroma to meaningfully extend patient lives. Read more about our strategic collaboration here: https://lnkd.in/dUkrgUCQ #cancer #oncology #biotechnology #innovation #researchcollaboration
-